多瑞醫藥(301075.SZ):與朗皓醫療簽署獨家代理協議
格隆匯5月11日丨多瑞醫藥(301075.SZ)公佈,公司近日與朗皓醫療科技(湖南)有限公司(簡稱“朗皓醫療”)簽訂了《銷售代理協議》。代理產品包括一次性可視雙腔支氣管插管(左、右腔型)、一次性可視氣管插管聯合套件(7.0,7.5)、可視喉罩(4號)、抗HPV生物蛋白敷料(3g*2支/盒);代理期限自2022年5月1日至2027年12月31日。
朗皓醫療研發的一系列可視化產品,帶有高清攝像頭,克服了當前雙腔支氣管導管安放及定位困難的問題,對支氣管損傷小,定位準確快速,可持續監測插管位置和術中情況,及時發現分泌物,及時處理,實現了氣道建立的精準性,極大提高了麻醉的安全性和有效性,並且可以減少纖支鏡的使用,降低消毒和設備損耗成本。
該次代理協議的簽署,有利於豐富公司品種結構和戰略佈局,提升公司整體競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.